New pill targets Cancer's 'Extra DNA' in desperate patients
NCT ID NCT05827614
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 23 times
Summary
This early-phase study tests an experimental oral drug, BBI-355, in people with advanced solid tumors (like certain breast, ovarian, lung, and other cancers) that have extra copies of cancer-driving genes. The goal is to find a safe dose and see if BBI-355, alone or with other targeted drugs, can shrink or control the tumors. About 85 adults whose cancer has worsened after standard treatments will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK (HNSCC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Florida Cancer Specialists
Lake Mary, Florida, 32746, United States
-
HealthONE
Denver, Colorado, 80218, United States
-
MD Anderson Cancer Center
Houston, Texas, 77054, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
NEXT Oncology
Fairfax, Virginia, 22031, United States
-
NEXT Oncology - Dallas
Irving, Texas, 75039, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
Sarcoma Oncology
Santa Monica, California, 90403, United States
-
The University of Kansas
Fairway, Kansas, 66205, United States
-
UCLA Medical Center
Los Angeles, California, 90095, United States
-
University of Washington, Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
University of Wisconsin
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.